跳至主要内容
临床试验/NCT01529372
NCT01529372已完成不适用

REnAL denervatIon by ultraSound Transcatheter Emission

ReCor Medical, Inc.4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年5月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
4
主要终点
Percentage of patients with device- or procedure-related adverse events

研究概览

简要总结

The REALISE trial is a single-arm, open-label, prospective, post market evaluation to be conducted on twenty (20) eligible patients with a twelve month follow-up period.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Resistant hypertension, as defined in the 2007 ESH-ESC guidelines
  • 18 years of age or older
  • Negative pregnancy test for female patients of childbearing potential
  • Willing and able to comply with follow-up requirements
  • Signed informed consent

排除标准

  • Secondary hypertension
  • Main renal arteries length < 20 mm
  • Main renal arteries diameter < 4 mm
  • Renal artery stenosis
  • Iliac/femoral artery stenosis precluding insertion of the catheter
  • Allergy to contrast media
  • Currently participating in the study of an investigational drug or device
  • Hemodynamics abnormality
  • Moderate to severe renal insufficiency

研究组 & 干预措施

Percutaneous renal denervation

Experimental

干预措施: PARADISE percutaneous renal denervation (Device)

结局指标

主要结局

Percentage of patients with device- or procedure-related adverse events

时间窗: 12 months

Anticipated adverse events include: * Puncture site-related events * Renal artery stenosis, aneurysm, dissection, or perforation * Renal infarction, acute kidney injury, or renal failure * Arterial and venous thromboembolic events (including myocardial infarction, stroke, aortic or peripheral artery disease, etc.)

Percentage of successful interventions

时间窗: Up to 24 hours

A successful intervention is defined by the ability to successfully: 1. Introduce the PRDS catheter 2. Position the PRDS catheter 3. Deliver ultrasound energy 4. Retrieve the PRDS catheter

次要结局

  • Change from baseline in anti-hypertensive medication intake(12 months)
  • Change from baseline in ambulatory blood pressure(12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验